Bone disease and HIV infection.
The high prevalence of bone demineralization among human immunodeficiency virus (HIV)-infected patients in the current therapeutic era has been described in multiple studies, sounding the alarm that we may expect an epidemic of fragility fractures in the future. However, despite noting high overall prevalences of osteopenia and osteoporosis, recent longitudinal studies that we review here have generally not observed accelerated bone loss during antiretroviral therapy beyond the initial period after treatment initiation. We discuss the continued progress toward understanding the mechanisms of HIV-associated bone loss, particularly the effects of HIV infection, antiretroviral therapy, and host immune factors on bone turnover. We summarize results of clinical trials published in the past year that studied the safety and efficacy of treatment of bone loss in HIV-infected patients and provide provisional opinions about who should be considered for bone disease screening and treatment.
Amorosa
Valerianna
V
Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Tebas
Pablo
P
D000328:Adult; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001847:Bone Diseases / Q000209:etiology*; D001851:Bone Diseases, Metabolic / Q000453:epidemiology / Q000209:etiology; D002648:Child; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000453:epidemiology / Q000209:etiology; D015995:Prevalence
D044966:Anti-Retroviral Agents